Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Poly-chemotherapy for Metastatic Colorectal Cancer
NCT02280694Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2015
- Primary completion
- Jan 2019
- Countries
- 1
- Sponsor
- Emek Medical Center
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Conditions
- metastatic colorectal cancer (mCRC)
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, cyclophosphamide, methotrexate and celecoxib in metastatic colorectal cancer (mCRC), sponsored by Emek Medical Center. Primary endpoint: Median Progression Free Survival up to 18 months. Started Jan 2015; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Metronomic Poly-chemotherapy
Capecitabine + Cyclophosphamide + Methotrexate + Celecoxib
03
Who it enrols
Patients with metastatic colorectal cancer progressing after all available standard therapies, with adequate organ function and no brain metastases or chronic inflammatory diseases.
04
Endpoints
Primary
Median Progression Free Survival
Beyond the preview
Go deeper on NCT02280694.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280694.